CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that management will present at the following investor conferences:
Jefferies Global Healthcare Conference on Thursday, November 18th at 3:00am EST
Evercore ISI HealthCONx Conference on Tuesday, November 30th at 10:30am EST
Access to the live webcast of these events, as well as an archived recording, will be available under the “Events” tab on the investor relations section of the Werewolf Therapeutics website at: https://investors.werewolftx.com/news-and-events/events.
About Werewolf Therapeutics, Inc.
Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. We are continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.
To learn more visit https//werewolftx.com.
Investor Contact:
Jonathan Nugent
Managing Director
Stern IR
jonathan.nugent@sternir.com
Media Contact:
Amanda Sellers
VERGE Scientific Communications
301.332.5574
asellers@vergescientific.com
Company Contact:
Ellen Lubman
Chief Business Officer
Werewolf Therapeutics
elubman@werewolftx.com
— HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize…
Provides financial flexibility by reducing near-term debt maturities, deferring principal redemption payment, and reducing near-term…
Innovative Solutions Transform Treatment for Burn Victims, Chronic Wounds, and Scar ReductionCHICAGO, Dec. 31, 2024…
TEL AVIV, Israel, Dec. 31, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or…
HOUSTON--(BUSINESS WIRE)--Hamershlag Private Capital Management Limited (HPCM), a leading health technology investment firm, has announced…
HOUSTON--(BUSINESS WIRE)--Hamershlag Private Capital Management Limited (HPCM), a leading health technology investment firm, has announced…